Search

Your search keyword '"Yousefi, Mehdi"' showing total 20 results
Start Over Author "Yousefi, Mehdi" Journal journal of reproductive immunology
20 results on '"Yousefi, Mehdi"'

5. The evaluation of CD39, CD73, and HIF-1 α expression besides their related miRNAs in PBMCs of women with recurrent pregnancy loss

Author

Parhizkar, Forough, primary, Kiani, Amirhossein, additional, Darzi, Satinik, additional, Motavalli, Roza, additional, Noori Dolama, Fatemeh, additional, Yousefzadeh, Yousef, additional, Aghebati-Maleki, Leili, additional, Pia, Helen, additional, Abdollahi-Fard, Sedigheh, additional, Mardi, Amirhossein, additional, Danaii, Shahla, additional, Ahmadian Heris, Javad, additional, Yousefi, Mehdi, additional, and Soltani-Zangbar, Mohammad Sadegh, additional

Published
2023
Full Text
View/download PDF

11. A new approach to the preeclampsia puzzle; MicroRNA-326 in CD4+ lymphocytes might be as a potential suspect

Author

Zolfaghari, Mohammad Ali, primary, Motavalli, Roza, additional, Soltani-Zangbar, Mohammad Sadegh, additional, Parhizkar, Forough, additional, Danaii, Shahla, additional, Aghebati-Maleki, Leili, additional, Noori, Mohammad, additional, Dolati, Sanam, additional, Ahmadi, Majid, additional, Samadi Kafil, Hossein, additional, Jadidi-Niaragh, Farhad, additional, Ahmadian Heris, Javad, additional, Mahmoodpoor, Ata, additional, Hejazi, Mohammad Saeid, additional, and Yousefi, Mehdi, additional

Published
2021
Full Text
View/download PDF

13. Intrauterine administration of autologous hCG- activated peripheral blood mononuclear cells improves pregnancy outcomes in patients with recurrent implantation failure; A double-blind, randomized control trial study

Author

Pourmoghadam, Zahra, primary, Soltani-Zangbar, Mohammad Sadegh, additional, Sheikhansari, Golshan, additional, Azizi, Ramyar, additional, Eghbal-Fard, Shadi, additional, Mohammadi, Hamed, additional, Siahmansouri, Homayoon, additional, Aghebati-Maleki, Leili, additional, Danaii, Shahla, additional, Mehdizadeh, Amir, additional, Hojjat-Farsangi, Mohammad, additional, Motavalli, Roza, additional, and Yousefi, Mehdi, additional

Published
2020
Full Text
View/download PDF

17. Metabolic syndrome mediates inflammatory and oxidative stress responses in patients with recurrent pregnancy loss

Author

Azizi, Ramyar, primary, Soltani-Zangbar, Mohammad Sadegh, additional, sheikhansari, Golshan, additional, Pourmoghadam, Zahra, additional, Mehdizadeh, Amir, additional, Mahdipour, Mahdi, additional, Sandoghchian, Siamak, additional, Danaii, Shahla, additional, Koushaein, Ladan, additional, Samadi Kafil, Hossein, additional, and Yousefi, Mehdi, additional

Published
2019
Full Text
View/download PDF

18. T cell Subsets in Peripheral Blood of Women with Recurrent Implantation Failure

Author

Ghaebi, Mahnaz, primary, Abdolmohammadi-Vahid, Samaneh, additional, Ahmadi, Majid, additional, Eghbal-Fard, Shadi, additional, Dolati, Sanam, additional, Nouri, Mohammad, additional, Talebi, Mehdi, additional, Hamdi, Kobra, additional, Marofi, Faroogh, additional, Aghebati-Maleki, Leili, additional, Jadidi-Niaragh, Farhad, additional, Dopour, Masoume, additional, and Yousefi, Mehdi, additional

Published
2019
Full Text
View/download PDF

19. Etiology and management of recurrent implantation failure: A focus on intra-uterine PBMC-therapy for RIF.

Author

Sheikhansari, Golshan, Pourmoghadam, Zahra, Danaii, Shahla, Mehdizadeh, Amir, and Yousefi, Mehdi

Subjects
*RECURRENT miscarriage, *PREMATURE ovarian failure, *FERTILIZATION in vitro, *KILLER cells, *INTRAVENOUS immunoglobulins
Abstract

• Implantation failure is one of the factors contributing to pregnancy rate reduction after IVF. • Local immunological cells and factors at implantation site play an important role in pregnancy process. • PBMC-therapy has positive effect, by developing required initial inflammation for implantation. Infertility is one of the most common problems among couples worldwide. Recurrent pregnancy loss, premature ovarian failure, recurrent implantation failure and etc. are common high prevalence disorders in societies. We will review the definition, causes and treatment of recurrent implantation failure disorder in recent studies. Implantation refers to the attachment of the embryo to the endometrial luminal surface and recurrent implantation failure (RIF) is defined as the failure to achieve a pregnancy after transferring high-grade embryos through at least three in vitro fertilization (IVF) cycles to the endometrium. The embryo factors, maternal age, uterine factors, and multifactorial effectors have been considered as the causes of implantation failure. In this review, we aim to focus on immunological factors and cells such as pro-inflammatory cytokines and dendritic cells, macrophages, decidual and uterine NK cells, as well as Th-1 cells. There are different types of treatment according to the cause of RIF including aspirin and low-molecular-weight heparin therapy, immunosuppressive drugs, intravenous immunoglobulins, and hydroxychloroquine. Among immunological recurrent implantation failure therapy, we will discuss the intrauterine PBMC-therapy in detail. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

20. A new approach to the preeclampsia puzzle; MicroRNA-326 in CD4 + lymphocytes might be as a potential suspect.

Author

Zolfaghari MA, Motavalli R, Soltani-Zangbar MS, Parhizkar F, Danaii S, Aghebati-Maleki L, Noori M, Dolati S, Ahmadi M, Samadi Kafil H, Jadidi-Niaragh F, Ahmadian Heris J, Mahmoodpoor A, Hejazi MS, and Yousefi M

Subjects
Adult, Case-Control Studies, Endoglin genetics, Female, Humans, Pre-Eclampsia blood, Pre-Eclampsia immunology, Pregnancy, T-Lymphocytes, Regulatory metabolism, Th17 Cells metabolism, Vascular Endothelial Growth Factor Receptor-1 genetics, Young Adult, Gene Expression Regulation immunology, MicroRNAs metabolism, Pre-Eclampsia genetics, T-Lymphocytes, Regulatory immunology, Th17 Cells immunology
Abstract

Background: Alongside many complications in understanding the etiology of Preeclampsia (PE), several determinants, such as the imbalanced proportion of anti-angiogenic/proangiogenic T-cell subsets, especially CD4 + (Th17/Treg), as well as alterations in the expression profile of related cytokines, miRNAs, and transcription factors might have been implicated in PE pathogenesis., Material and Method: After sample collection and preparation, CD4 + cells were isolated from PE and non-PE pregnant woman and were cultured. Furthermore, analysis such as flow cytometry, real-time PCR, western blotting, and ELISA were performed to assess determinants related to PE manifestation, including sFlt-1, sEng, STAT-3, RORγt, SMAD-7, Foxp3, IL-17, IL-22, Ets-1, and miRNA-326., Results: Our results showed that the miRNA-326 expression level increased in CD4 + Cells and Th17 in PE patients which downregulated Ets-1 expression that acts as a negative control for Th17 development. Furthermore, we showed that the number and expression level of Th17 s and transcription factor RORγt escalated, respectively. While Treg and its related transcription factor (Foxp3) demonstrated a decrease. Flow cytometry analysis illustrated that the Th17/Treg ratio increased in PE. Additionally, we demonstrated that expression and concentration levels of cytokines (IL-17 and IL22) and anti-angiogenic molecules (sEng and sFlt-1) soared in isolated CD4 + cells from PE patients, which could be correlated with PE pathogenicity., Conclusion: In conclusion, we comprehensively evaluated immunological factors and molecules involved in PE manifestation. Interestingly, the CD4 + T-cell subset could be an extra source of antiangiogenic factors for the maintenance of this hypertension disorder., (Copyright © 2021 Elsevier B.V. All rights reserved.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results